Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell Lymphoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The purpose of this study is to establish the safety, tolerability, pharmacokinetics and RP2D (Recommended Phase II Dose) of orally administered HZ-A-018 in patients with B cell lymphoma who have at least failed or relapsed after first-line treatment.
Epistemonikos ID: 09d7b82e0b03176253ac915223d4c8f0b493e2d2
First added on: May 06, 2024